Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. - Wikidata - wikimedia - TriplyDB

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.

http://www.wikidata.org/entity/Q34247727

about

Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies Use of NSAIDs in treating patients with arthritis Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease Celecoxib for schizophrenia Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species Molecular cancer prevention: Current status and future directions Chemoprevention in familial adenomatous polyposis Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1 Integration of epidemiology, immunobiology, and translational research for brain tumors Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks Amelioration of amyloid-β-induced deficits by DcR3 in an Alzheimer's disease model.Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema.A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.Biological activity of celecoxib in the bronchial epithelium of current and former smokers.Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks.Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results Randomized controlled trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety.Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline Targeted deletions of cyclooxygenase-2 and atherogenesis in mice.Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers.Current concepts in colorectal cancer prevention Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evi Inducible nitric oxide synthase gene deletion exaggerates MAPK-mediated cyclooxygenase-2 induction by inflammatory stimuli Primary prevention of colorectal cancer.Chemoprevention in patients with genetic risk of colorectal cancers Cyclooxygenases: mediators of UV-induced skin cancer and potential targets for prevention.Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium.Physiology. COX-2 inhibitors and cardiovascular risk.Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.Cyclooxygenase-2 inhibition attenuates abdominal aortic aneurysm progression in hyperlipidemic mice.Animal models of colitis-associated carcinogenesis.Cyclo-oxygenase-2 inhibition and endothelium-dependent vasodilation in younger vs. older healthy adults.Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue.Celecoxib for osteoarthritis.

P2860

Q21144617-251062C5-8B5B-4770-8B4A-397757D4B9E2 Q21195252-CB678EB5-1CD9-4684-B313-4AA05DB3FCF6 Q24203739-A6432DF3-AFB0-4A84-A7F7-24B19AEF1E22 Q24235746-44101E0F-4D4F-420F-AFD3-70B72B8D6235 Q24601392-31288406-9873-46EE-B588-E23D2CD82089 Q24619410-8F8DE5C7-5338-49F4-BAB7-53CBBA3F2F9C Q26784322-E1ED014B-FFCC-4B6B-B531-1B27B2968554 Q26797207-0C6BD0F3-0970-434F-A94E-9DFE4C62112E Q27023845-6F6A37B9-EB70-486B-917B-A0B4523A9C49 Q27658412-6F860A19-33AB-47D7-AD14-071F4141413C Q28397886-D0C4EBA4-F307-470B-93CD-254168C37C80 Q28472972-35DB3C94-F1B4-4BF6-9E88-3106B98DB9E3 Q28742977-C8119700-477E-469C-B1B0-42D901D612E8 Q30498812-2FD09207-12D0-4203-B5FA-4B87AEAEBA9F Q30629677-E087E799-44E3-4FCB-9106-B1396CDB2D9A Q30846817-9ADAA9EF-7297-4BCF-B378-78A0E3496A4D Q33416977-9CD581AF-6E1C-4CF1-97CE-5ADBF8520490 Q33521026-C877773F-68EB-4EAB-A77D-B37CE9A34C0B Q33640357-D3254119-704D-4355-A68E-3FCA260B339B Q33640402-328DF749-351A-468D-871B-4ED0A94BC0AA Q33678007-EC4BB4F9-DCA6-4415-BD22-5832E4BC3227 Q33836869-044E1392-F9CC-447A-B9C0-E1BBD271EC46 Q33989306-E9C45B2D-AAEF-406C-ABBB-AC5F5C91B27D Q33995716-148C7389-F8B1-4590-8A9F-8977B1E6001C Q34019117-61E0DE66-B445-43F9-BC58-CE8E8DCDEFD3 Q34021188-286B4C70-0C37-4E0F-8C85-3F88E3CEA158 Q34065803-8AB6BF60-912C-40BA-9C5D-07F06C0BF556 Q34148370-C0ECE619-8C3C-4960-85EE-B331EC23B5A0 Q34150541-91D99B1F-E55D-4101-B63A-EC7245D17A1D Q34165145-6AF805E5-C8FF-454C-9561-2E1A0169F3BE Q34170508-14BD4B23-1DFA-46F1-8E0A-1E9406B307F3 Q34195623-24877388-87E2-414F-A684-C9AD7FE021BC Q34209497-14D91A0C-8251-47AD-8DB7-B37774C1A868 Q34281737-76B11802-6B0F-40C5-AEB5-AC8F6FC6A854 Q34406418-C53829A5-DBAF-45B7-89A7-9B3C49AC7B52 Q34499514-953F9F47-1FD9-4B55-AA24-77CC7D6781A3 Q34512820-5AAF3206-733E-4323-9BBF-E6830BAA7F99 Q34554429-F5AB7DA9-A375-4E68-B8D1-1A8042BB5E4A Q34556489-5057B13D-6D3B-47C2-BC55-6E3897539A66 Q34557021-9EFAAFF5-AC59-475B-B9E1-75637D2829DF

P2860

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.

http://www.wikidata.org/entity/Q34247727

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Cardiovascular risk of celecox ...... e cross trial safety analysis.

@ast

Cardiovascular risk of celecox ...... e cross trial safety analysis.

@en

Cardiovascular risk of celecox ...... e cross trial safety analysis.

@nl

type

label

Cardiovascular risk of celecox ...... e cross trial safety analysis.

@ast

Cardiovascular risk of celecox ...... e cross trial safety analysis.

@en

Cardiovascular risk of celecox ...... e cross trial safety analysis.

@nl

prefLabel

Cardiovascular risk of celecox ...... e cross trial safety analysis.

@ast

Cardiovascular risk of celecox ...... e cross trial safety analysis.

@en

Cardiovascular risk of celecox ...... e cross trial safety analysis.

@nl

P1433

Q34247727-331291D7-AED6-4BAE-8DE1-1D6F5E785B89

P1476

Q34247727-438AC828-52CC-460D-9258-40E092243CBC

P2093

Q34247727-0389E473-641F-4F81-8A8F-41DF21E470E5

Q34247727-0B6726BD-4EED-4587-B073-06EEEAC621D4

Q34247727-0D88870F-2043-462C-84F1-B18DFFBD041C

Q34247727-1745C1E4-138D-4416-BC16-136F62C57DAE

Q34247727-26790C4F-870F-4B3B-A2E4-CBC324FEF82B

Q34247727-34EBA42B-3EF2-4434-899A-59C05D32BBEB

Q34247727-4912026D-1611-4609-9C7A-96027F6C76A4

Q34247727-588FC215-B8F2-407B-BFD6-7A198DF6DF71

Q34247727-70F3890C-F387-4DA0-89CB-513CC0C38062

Q34247727-7A32FD86-F3D5-4D31-80F5-7F35D0B869DF

P2860

Q34247727-0BA77CFC-A4C7-4BCD-B9E3-58E0CFFDFB73

Q34247727-14E671A2-0A94-454E-8745-B3918728D18E

Q34247727-212D7FC3-8DFF-496A-A301-BCE6507A0958

Q34247727-21A950C7-4CF5-49A7-B207-F05FE4D9B335

Q34247727-273D8815-B9E4-4073-A439-BB1C1F20C293

Q34247727-2E04DF05-B3FA-4020-A0A9-FD9744C70806

Q34247727-3D9361BD-E241-48A2-9D00-10CE1B4283BB

Q34247727-421A8670-BBAF-4BC8-B0B6-4C182AEF3272

Q34247727-49E798A7-937F-4FA9-A95B-D7519946C743

Q34247727-4B44CB1D-E88E-4EA3-8D4E-1286459E1D7A

P304

Q34247727-6B9BE40A-0382-4CE4-9A81-D517996C0317

P31

Q34247727-A8A75E00-B3EB-46A4-801A-5FBFECB731AC

Q34247727-aeaf5fee-f767-4cd8-8edd-ccd7128d63b4

P356

Q34247727-C6D73518-5F4B-47E6-9539-0FB2717240C6

P407

Q34247727-D3D025F7-3B02-4CF9-9322-4FFE99D5FA3A

P433

Q34247727-84EDFB6B-752A-4937-8EB7-0F4042D1577D

P478

Q34247727-FA71C1D6-9357-43CA-8D8B-DF61483058B8

P50

Q34247727-01C02504-EA68-4397-A40F-653C24C4AABE

Q34247727-7628AA77-6F44-4C8B-8B0D-B4589230BBB1

P577

Q34247727-ADE02FA4-6BAB-4B54-AEDB-62C2BA63DE85

P698

Q34247727-DACCAB8C-94E6-429D-A77C-C609DEDC1B4A

P921

Q34247727-B04FB65A-C8C1-4066-9991-DA128C0B3A0E

Q34247727-CAAA8CAF-D2B6-4CA0-AA5F-DBA9A557D6CF

P932

Q34247727-2D534EAE-12F7-4848-A632-CDABC64B1B27

P356

CIRCULATIONAHA.108.764530

P1433

P1476

Cardiovascular risk of celecox ...... e cross trial safety analysis.

@en

P2093

Barbara Martin

http://www.w3.org/2001/XMLSchema#string

Bernard Levin

http://www.w3.org/2001/XMLSchema#string

Cross Trial Safety Assessment Group

http://www.w3.org/2001/XMLSchema#string

Curtis L Meinert

http://www.w3.org/2001/XMLSchema#string

Ernest Hawk

http://www.w3.org/2001/XMLSchema#string

Gretchen Arndt

http://www.w3.org/2001/XMLSchema#string

Jaye Viner

http://www.w3.org/2001/XMLSchema#string

Jonghyeon Kim

http://www.w3.org/2001/XMLSchema#string

Joseph L Pater

http://www.w3.org/2001/XMLSchema#string

Monica M Bertagnolli

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of Coronary Heart Disease Using Risk Factor Categories

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

Celecoxib for the prevention of sporadic colorectal adenomas

Celecoxib for the prevention of colorectal adenomatous polyps

Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

P304

2104-2113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.108.764530

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18378608

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

2965408

http://www.w3.org/2001/XMLSchema#string